Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the…

The average benefit of zolpidem over placebo is about 20 minutes of faster sleep onset — how will we judge whether it's doing enough for me to be worth the risks?

gold standard92/100

Top of the evidence hierarchy, independently funded. how we score evidence

FDA approvedzolpidem (Ambien, Edluar, Intermezzo)ambienedluarintermezzo

Across 13 placebo-controlled trials submitted to the FDA (4,378 people), z-drugs including zolpidem shortened lab-measured time to fall asleep by about 22 minutes versus placebo — a real but modest benefit, with a large share of the overall improvement also occurring on placebo.

Worth asking

The average benefit of zolpidem over placebo is about 20 minutes of faster sleep onset — how will we judge whether it's doing enough for me to be worth the risks?

What it is FDA approved for

Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.

  • Short-term treatment of insomnia characterized by difficulties with sleep initiation

Source

Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration — Huedo-Medina TB, et al. (2012)

Top-tier peer-reviewed journal

Read the source: https://doi.org/10.1136/bmj.e8343

DOI: 10.1136/bmj.e8343

How this was scored

Study design
Meta-analysis of randomised trials
Funding
Independently funded
Published in
Top-tier peer-reviewed journal
Sample size
4,378
Preregistered
No
Conflicts disclosed
Yes
Independent of proponent
Yes
Retracted
No

Read the full scoring rubric, including what it can't tell you.

Published August 19, 2026.

Questions

How strong is the evidence behind this?

Resolv rates this source "gold standard". Top of the evidence hierarchy, independently funded. It scores 92 out of 100 on our published rubric. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.

What is the source for this?

Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration — Huedo-Medina TB, et al. (2012). Published in: Top-tier peer-reviewed journal. DOI: 10.1136/bmj.e8343. The full source is linked on this page so you can read it yourself.

Who paid for this research, and does that matter?

Study design: Meta-analysis of randomised trials. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.

Is zolpidem (Ambien, Edluar, Intermezzo), ambien, edluar, intermezzo FDA approved?

Yes — FDA approved for Short-term treatment of insomnia characterized by difficulties with sleep initiation. Approval is for a specific indication, not for everything the drug is prescribed for.

Is this medical advice?

This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.

This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.